Astellas Pharma ADR (ALPMY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 03/31
| 12-2020 | 09-2020 | 06-2020 | 12-2019 | 09-2019 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 1,576,579 | 837,455 | 560,213 | 2,200,502 | 1,502,731 |
| Depreciation Amortization | 519,264 | 337,845 | 167,391 | 444,314 | 289,658 |
| Accounts receivable | 51,696 | 167,931 | -123,002 | -270,802 | -64,589 |
| Accounts payable and accrued liabilities | -568,243 | -477,567 | -281,065 | -392,638 | -227,915 |
| Other Working Capital | -631,987 | -395,599 | -464,544 | -953,313 | -507,455 |
| Other Operating Activity | 1,214,064 | 610,558 | 341,887 | 538,605 | -47,002 |
| Operating Cash Flow | $2,161,373 | $1,080,624 | $200,880 | $1,566,668 | $945,429 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -156,941 | -130,970 | -70,475 | -223,293 | -153,311 |
| Net Acquisitions | -143,069 | -16,046 | -15,503 | -118,800 | -47,225 |
| Purchase Sale Intangibles | -345,091 | -273,408 | -238,787 | -234,563 | -147,117 |
| Other Investing Activity | -350,246 | -212,863 | -177,491 | -342,258 | -232,407 |
| Investing Cash Flow | $-650,256 | $-359,879 | $-263,469 | $-684,351 | $-432,943 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | -777,600 | -582,800 | -279,000 | N/A | N/A |
| Common Stock Repurchased | -8,467 | -8,281 | -8,184 | -350,115 | -11,039 |
| Dividend Paid | -731,107 | -349,210 | -345,495 | -676,559 | -333,228 |
| Other Financing Activity | -127,661 | -91,227 | -46,007 | -125,460 | -83,123 |
| Financing Cash Flow | $-1,644,835 | $-1,031,518 | $-678,686 | $-1,152,134 | $-427,391 |
| Exchange Rate Effect | 19,699 | 13,198 | 11,625 | -38,116 | -82,370 |
| Beginning Cash Position | 3,056,554 | 2,992,875 | 2,961,036 | 2,861,881 | 2,892,988 |
| End Cash Position | 2,942,534 | 2,695,300 | 2,231,386 | 2,553,938 | 2,895,713 |
| Net Cash Flow | $-114,019 | $-297,576 | $-729,650 | $-307,942 | $2,725 |
| Free Cash Flow | |||||
| Operating Cash Flow | 2,161,373 | 1,080,624 | 200,880 | 1,566,668 | 945,429 |
| Capital Expenditure | -219,984 | -131,177 | -70,550 | -285,954 | -154,027 |
| Free Cash Flow | 1,941,389 | 949,447 | 130,330 | 1,280,714 | 791,402 |